GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CannLabs Inc (OTCPK:CANL) » Definitions » Total Liabilities

CannLabs (CannLabs) Total Liabilities : $3.50 Mil (As of Mar. 2015)


View and export this data going back to 2010. Start your Free Trial

What is CannLabs Total Liabilities?

CannLabs's Total Liabilities for the quarter that ended in Mar. 2015 was $3.50 Mil.

CannLabs's quarterly Total Liabilities increased from Sep. 2014 ($1.79 Mil) to Dec. 2014 ($2.95 Mil) and increased from Dec. 2014 ($2.95 Mil) to Mar. 2015 ($3.50 Mil).

CannLabs's annual Total Liabilities increased from Dec. 2012 ($0.03 Mil) to Dec. 2013 ($0.19 Mil) and increased from Dec. 2013 ($0.19 Mil) to Dec. 2014 ($2.95 Mil).


CannLabs Total Liabilities Historical Data

The historical data trend for CannLabs's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CannLabs Total Liabilities Chart

CannLabs Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Total Liabilities
Get a 7-Day Free Trial 0.09 0.06 0.03 0.19 2.95

CannLabs Quarterly Data
Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 1.16 1.79 2.95 3.50

CannLabs Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CannLabs's Total Liabilities for the fiscal year that ended in Dec. 2014 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.509+(1.438+2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.95

Total Liabilities=Total Assets (A: Dec. 2014 )-Total Equity (A: Dec. 2014 )
=1.318--1.629
=2.95

CannLabs's Total Liabilities for the quarter that ended in Mar. 2015 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.677+(1.825+-2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=3.50

Total Liabilities=Total Assets (Q: Mar. 2015 )-Total Equity (Q: Mar. 2015 )
=1.126--2.376
=3.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CannLabs Total Liabilities Related Terms

Thank you for viewing the detailed overview of CannLabs's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


CannLabs (CannLabs) Business Description

Traded in Other Exchanges
N/A
Address
519 N. Sam Houston Parkway E., Suite 500, Houston, TX, USA, 77060
CannLabs Inc is based in Houston Texas and is a diversified inventory blockchain platform company. The company also has an entertainment division which also includes ownership of a Private Label Apparel line (Colorblind). The company is involved in four sectors: Manufacturing, Apparel, Music, and Video Game Design.

CannLabs (CannLabs) Headlines

From GuruFocus

CannLabs, Inc's 2021 Annual General Meeting Announcement

By PRNewswire PRNewswire 12-07-2021